Edap Tms (EDAP) Cut to “Hold” at Zacks Investment Research

Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other research firms have also issued reports on EDAP. ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a report on Friday, October 6th. HC Wainwright restated a “buy” rating and issued a $6.50 target price on shares of Edap Tms in a report on Monday, October 9th.

Edap Tms (EDAP) traded down $0.02 during mid-day trading on Friday, reaching $2.70. 73,809 shares of the company’s stock traded hands, compared to its average volume of 51,946. Edap Tms has a fifty-two week low of $2.25 and a fifty-two week high of $3.85. The company has a quick ratio of 2.35, a current ratio of 2.96 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $79.74, a price-to-earnings ratio of -33.75 and a beta of 1.02.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, November 15th. The medical equipment provider reported ($0.02) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02). Edap Tms had a negative net margin of 5.36% and a positive return on equity of 7.85%. The business had revenue of $8.44 million during the quarter, compared to analyst estimates of $11.05 million. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. research analysts anticipate that Edap Tms will post -0.01 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Archon Capital Management LLC lifted its holdings in Edap Tms by 12.5% during the 3rd quarter. Archon Capital Management LLC now owns 843,489 shares of the medical equipment provider’s stock valued at $2,514,000 after buying an additional 93,762 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in Edap Tms by 520.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 323,528 shares of the medical equipment provider’s stock valued at $964,000 after buying an additional 271,367 shares in the last quarter. Perkins Capital Management Inc. increased its position in Edap Tms by 184.3% during the 1st quarter. Perkins Capital Management Inc. now owns 276,500 shares of the medical equipment provider’s stock valued at $766,000 after purchasing an additional 179,250 shares during the period. Wells Fargo & Company MN increased its position in Edap Tms by 1.0% during the 3rd quarter. Wells Fargo & Company MN now owns 193,655 shares of the medical equipment provider’s stock valued at $562,000 after purchasing an additional 2,000 shares during the period. Finally, Hilton Capital Management LLC increased its position in Edap Tms by 43.1% during the 2nd quarter. Hilton Capital Management LLC now owns 83,000 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 25,000 shares during the period. Institutional investors own 10.34% of the company’s stock.

WARNING: “Edap Tms (EDAP) Cut to “Hold” at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/19/edap-tms-edap-cut-to-hold-at-zacks-investment-research.html.

Edap Tms Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply